Biomedicine and Pharmacotherapy Review Time
Biomedicine & Pharmacotherapy's review timeline, where delays usually happen, and what the timing means if you are preparing to submit.
While you wait
Waiting on Biomedicine & Pharmacotherapy? Get your next move ready.
The Biomedicine & Pharmacotherapy wait is out of your hands; the next move isn't. Scan your next manuscript free, or run this paper through the scan to see what reviewers typically push back on, so the revision response is ready when the decision lands.
Biomedicine & Pharmacotherapy review timeline: what the data shows
Time to first decision is the most actionable number. What happens after varies by manuscript and reviewer availability.
What shapes the timeline
- Desk decisions are fast. Scope problems surface within days.
- Reviewer availability is the main variable after triage. Specialized topics take longer to assign.
- Revision rounds reset the clock. Major revision typically adds 6-12 weeks per round.
What to do while waiting
- Track status in the submission portal, status changes signal active review.
- Wait at least the journal's stated median before sending a status inquiry.
- Prepare revision materials in parallel if you expect a revise-and-resubmit decision.
Quick answer: for Biomedicine and Pharmacotherapy review time, a current Elsevier author-story page reports an average 2.4 weeks to first decision. The exact SciRev page has N=4 reports, including 49 days for immediate rejection and 0.8 months for the first review round. An early editorial decision and full external review are different routes.
The publisher figure is timing context published on a journal page, while SciRev is a small author-reported sample. Use both to plan communication and revision capacity, not to predict a specific decision. A pharmacotherapy manuscript can move quickly at triage but take longer once editors need specialist assessment of mechanism, disease model, safety, and translational relevance.
How this page was researched: we checked the current Biomedicine & Pharmacotherapy publisher material, author guidance, submission route, and exact SciRev record. This page helps authors distinguish editorial screening from a full evidence-focused review before submitting.
Start with the Biomedicine & Pharmacotherapy submission guide, the Biomedicine & Pharmacotherapy journal profile, and the Phytomedicine submission guide if a natural-product or translational pharmacology comparison would help.
Last reviewed July 20, 2026.
Biomedicine and Pharmacotherapy review time at a glance
Stage | Planning figure | What it means |
|---|---|---|
Immediate rejection | 49 days | Small SciRev signal across four community reports; do not treat it as a service standard. |
First decision | 2.4 weeks | Current timing context reported in an Elsevier author-story page. |
First review round | 0.8 months | SciRev community signal for the first external-review round. |
Accepted handling | 1.0 month | Small SciRev signal for accepted manuscripts. |
Review rounds | 2.0 rounds | Community average across the four reports. |
Review reports | 2.0 reports | Community average, not a guarantee of reviewer count. |
What the timing sources support
The official Biomedicine & Pharmacotherapy journal page and guide for authors provide live scope, article-preparation, and workflow context. An Elsevier author-story page currently says the average time to first decision is 2.4 weeks. That is an aggregate figure, not a commitment that every manuscript will be externally reviewed or decided in that time.
The exact Biomedicine and Pharmacotherapy SciRev page has N=4 reports. It currently shows 0.8 months to first review, 1.0 month accepted handling, 49 days for immediate rejection, two review rounds, and two reports. The small sample is useful for separating reported reviewed-paper timing from the publisher’s first-decision context, but it cannot establish a dependable median.
The journal profile emphasizes pharmacotherapy, disease-linked biomedicine, therapeutic mechanisms, and translational evidence. That framing matters during triage: a strong molecular result may still need a clear therapeutic decision, disease context, model boundary, and evidence chain before editors can send it to reviewers.
A practical review timeline
Elapsed time | Likely work | Useful author action |
|---|---|---|
Days 0 to 7 | File checks, declarations, ethics, scope, and editor routing | Make the therapeutic contribution and model context visible in the title, abstract, and cover letter. |
Weeks 1 to 3 | Editorial screen or reviewer invitations | Recheck consent, ethics, data availability, reporting checklists, and figure-source files. |
Weeks 3 to 8 | External reports on mechanism, controls, model validity, and clinical relevance | Build a response map linking every major claim to an experiment, control, dataset, and limitation. |
Revision | New analysis, model clarification, added control, or narrowed therapeutic claim | Answer point by point with exact figure, supplement, and line references. |
After about eight weeks under review | A reasonable point for one factual inquiry | Use the official Editorial Manager route once and keep the work exclusive. |
Failure patterns that slow a Biomedicine and Pharmacotherapy decision
A therapeutic conclusion is larger than the evidence package. A cell, pathway, or compound signal does not automatically establish pharmacotherapy relevance. Explain which disease decision the result changes, what population or model it can speak to, and what remains untested.
The mechanism is a narrative rather than a discriminating test. Association, docking, expression change, and pathway enrichment can suggest a direction. Reviewers still need controls or perturbations that distinguish plausible mechanisms, or a claim carefully limited to what the data show.
The disease model is under-described. State why the model represents the claimed biology, how randomization, blinding, exclusions, sample size, sex, timing, and endpoints were handled, and where model limitations constrain translation.
Safety, dose, and exposure sit outside the central argument. A pharmacotherapy claim should make dose rationale, route, exposure window, adverse observations, and therapeutic window easy to find. Do not ask reviewers to reconstruct them from scattered methods and supplements.
The paper is mainly descriptive biology or chemistry. If the therapeutic implication depends on a future study, say so. A disciplined claim boundary is more persuasive than retrofitting pharmacotherapy language to a preliminary activity screen.
Submit if
- The abstract says what therapeutic or pharmacological decision the study advances, not only what changed in a model.
- Mechanistic, functional, and translational evidence match the strength of the conclusion.
- Methods, ethics, data availability, controls, and reporting details allow the evidence to be audited.
- You can plan for a fast first-decision aggregate while retaining capacity for a deeper external review and revision.
Readiness check
While you wait on Biomedicine & Pharmacotherapy, scan your next manuscript.
The scan takes about 1-2 minutes. Use the result to decide whether to revise before the decision comes back.
Think twice if
- The manuscript’s primary contribution is a descriptive activity signal with no credible therapeutic mechanism or disease context.
- The in-vivo, clinical, or exposure evidence cannot support the proposed intervention claim.
- The cover letter leaves editors to infer why the result belongs in pharmacotherapy rather than general biomedical science.
- You need the 2.4-week aggregate to mean a guaranteed peer-review outcome.
What to do while waiting
- Create one claim-to-evidence table covering mechanism, disease model, dose, route, controls, endpoint, statistical unit, and limitation.
- Reconcile abstract, figures, methods, supplement, ethics statement, data-availability note, and cover letter so the therapeutic framing is consistent.
- Prepare response-ready files for randomization, blinding, exclusions, sample size, adverse effects, model validity, and data provenance.
- Keep the manuscript exclusive and use one factual portal inquiry only after roughly eight weeks of unchanged external-review status.
Pharmacotherapy revision map
Reviewer concern | Strong revision action | Weak revision action |
|---|---|---|
Therapeutic relevance | State the disease decision, target population, and evidence boundary. | Repeat that the compound may be useful. |
Mechanism | Add a discriminating control or narrow the mechanistic claim. | Treat correlation as causal proof. |
Model validity | Explain model fit, design choices, and transfer limits. | Call every preclinical signal clinically relevant. |
Dose and safety | Make exposure, route, adverse findings, and uncertainty visible. | Report efficacy alone. |
In our pre-submission review work with Biomedicine and Pharmacotherapy manuscripts
In our pre-submission review work with Biomedicine and Pharmacotherapy manuscripts, the strongest packages make a therapeutic argument that a reviewer can audit from the first page onward. They do not treat a pathway observation, a docking result, or a reduction in one disease-model endpoint as interchangeable with a pharmacotherapy contribution. Instead, the abstract names the intervention or biological leverage point, the disease decision, the model, the main evidence, and the boundary on what can be claimed.
The Biomedicine and Pharmacotherapy abstract opens with activity but not therapeutic consequence. We ask authors to name the clinical or preclinical problem and specify what would change if the result holds. The drug, modality, route, target, comparator, and disease setting should make the significance legible without turning an early-stage finding into a treatment promise.
The Biomedicine and Pharmacotherapy mechanism section confuses a pathway marker with causal support. We check whether perturbation, rescue, orthogonal measurement, time ordering, or a competing explanation has been considered. If not, authors can often improve the paper by narrowing the mechanism language and clearly labeling the next discriminating experiment.
The Biomedicine and Pharmacotherapy model does not carry the translational claim. We look for model selection rationale, cohort or animal characteristics, randomization, blinding, exclusions, statistical unit, endpoint timing, and limits on transfer to patients. A concise limitation paragraph is more useful than implying the model is a clinical surrogate.
The Biomedicine and Pharmacotherapy dose story is disconnected from efficacy. Reviewers need route, schedule, concentration or exposure, dose rationale, tolerability observations, and the relationship between the dose and the claimed mechanism. We help authors gather this information into figures, methods, and supplements rather than leaving it dispersed.
The Biomedicine and Pharmacotherapy revision response says the work is novel without resolving the requested evidence gap. We recommend a direct response table: what was requested, what was added or changed, where it appears, and whether it strengthens or limits the conclusion. When a requested experiment is not feasible, explain why and narrow the claim instead of substituting rhetoric.
The Biomedicine and Pharmacotherapy paper presents a broad therapeutic future for a narrow endpoint. We check whether the endpoint is surrogate, intermediate, functional, disease-modifying, or safety-related, and whether the conclusion matches that level. Explicitly distinguishing proof of principle from clinical readiness protects the paper’s credibility while preserving its promise.
Before upload, a Biomedicine & Pharmacotherapy readiness review can test the therapeutic argument, evidence chain, reporting risks, and likely revision pressure.
Frequently asked questions
A current Elsevier author-story page reports an average 2.4 weeks to first decision. The exact SciRev page has four reports: 0.8 months for the first review round and 1.0 month for accepted handling. These are different measures and neither is a promise for an individual paper.
No. A first decision can be an editorial triage outcome or a decision after external review. The SciRev record separately reports a 0.8-month first review round, so authors should not equate the first-decision aggregate with the full review path.
Friction often comes from a therapeutic claim that exceeds its mechanism, model, safety, or translational support; unclear controls; incomplete reporting; or a paper that is primarily descriptive biology or chemistry.
If the manuscript is clearly under external review and has no meaningful status change after roughly eight weeks, one concise factual inquiry through Editorial Manager is reasonable.
Sources
Final step
Done interpreting the status? Put the wait to work.
The Biomedicine & Pharmacotherapy decision will arrive on the journal's clock. What you control is what's next: scan your next manuscript free, or run this paper through the scan so the likely reviewer pushback is mapped before the revision request lands.
Free scan, no card needed.
Target journal carried over: Biomedicine & Pharmacotherapy
Anthropic Privacy Partner. Your manuscript is never used to train any model.